Ryan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Ryan C. DeCoste, MD, QEII Health Sciences Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Merkel cell carcinoma is a relatively rare but highly aggressive skin cancer, according to DeCoste. A previous publication identified a subset of these patients, making up approximately 80% of cases, are associated with a viral oncogenic pathogenesis, which incorporates Merkel cell papilloma virus DNA into precursor cells for subsequent tumorigenesis. However, subsequent to this, a smaller subset was thought not to be associated with this virus and more likely due to UV-induced DNA damage.
Based on these observations, Merkel cell carcinoma can be classified in 1 of 2 categories: virus-positive or virus-negative, and these subsets each have distinct mutational profiles, DeCoste notes.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More